BIONATURIS has positioned as a partner of reference in Animal Health by bringing innovative premium products to the market place. By a B2B business model, Bionaturis offers a rich portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. From outstanding feed supplements to new generation of biological vaccines, Bionaturis is engaged to target unmet needs in FPAs (Food Production Animals) and pets.

Check below the stage and license availability of our commercial and late-stage programs.

To know more about them or our earlier stage programs, feel free to email us at


Program Description Indication/Effect Specie Stage and availability
Food Production Animals. Non-therapeutic non-prescription products
Modulin An innovative peptide-based nutritional supplement designed to increase livestock productivity. Immune enhancer and growth promoter Poultry MODULIN AVIS sheet
IgY An innovative IgYs-based feed to prevent and to treat Neonatal Calf Diarrhea (NCD). Immune enhancer Bovine IgY NCD FAQs
Immuno A feed supplement formulated based on two specific Lactobacillus plantarum strains, vitamins and minerals, which contributes to the normal function of the immune system. Immune enhancer and growth promoter Bovine IMMUNO info
Food Production Animals. Prescription/therapeutics products
BNT007 Recombinant multivalent VLP antigen Viral infection Poultry Antigen available for registration and commercial license. Market restrictions in China
BNT010 Recombinant DIVA antigen Viral infection Swine Antigen available for registration and commercial license. Market restrictions in China
BNT015 Recombinant VLP antigen Viral infection Swine Antigen available for registration and commercial license. Market restrictions in China
PETs. Non-therapeutic non-prescription products
New outstanding products available soon
PETs. Prescription/therapeutics products
BNT005 Vaccine. Recombinant fusion protein incorporating a trigger of cellular response. Canine visceral leishmaniasis Dogs Market restrictions worldwide
New outstanding products available soon



Forward-Looking Statement

This page includes “forward-looking statements”. These statements are based upon the current beliefs and expectations of Bionaturis’ management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Bionaturis’ ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Bionaturis’ patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Bionaturis undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

No Duty to Update

The contained in this page was current as of March 8, 2017. While this pipeline status remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after October 24, 2016.